Hangzhou Tigermed Consulting Co.,Ltd. (ASX: 300347) has announced the completion of a significant share repurchase initiative.
According to a company filing, as of June 30, 2026, the firm had repurchased a total of 20,963,478 of its own shares through a dedicated securities account using centralized bidding transactions.
This repurchased volume represents 2.4347% of the company's current total issued share capital and accounts for 2.8410% of its total A-share capital.